Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...
It is designed to address one of the biggest shortcomings of current existing γδ TCEs – insufficient numbers of γδ T cell ...
In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in ...
Discover the newly identified proteins to predict ICANS, improving the safety of CAR-T cell therapy by identifying high-risk ...
Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...
A novel mouse model offers definitive evidence that a single inhibitory receptor family governs the critical natural killer cell functions of licensing and missing-self.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback